Institut Bergonie - Unicancer Nouvelle Aquitaine - Service Oncologie medicale | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)	Adnexal Diseases, Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, benign urinary system neoplasm, biliary tract disorder, breast disorder, breast neoplasm, cervix disorder, colonic disorder, colorectal neoplasm, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gallbladder disorder, gallbladder neoplasm, gastric neoplasm, gastrointestinal stromal tumor, gonadal disorder, intestinal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, rectal disorder, sarcoma, skin disorder, stomach disorder, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder	Recruiting	Phase 2	2026-10-02		NCT06760819
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)	Advanced Non-small Cell Lung Cancer; EGFR Mutation; HER2 Mutation	Recruiting	Phase 1 / Phase 2	2026-08-12		NCT05099172
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors	Disease Attributes, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Thoracic Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, squamous cell carcinoma, triple-negative breast carcinoma	Active, not recruiting	Phase 1	2026-07-07		NCT05537740
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer	cancer, neoplasm	Active, not recruiting	Phase 3	2026-07-07		NCT04464226